Valuation dashboard for Evogene Ltd. (EVGN) with P/E N/A, P/B -1.98, EV/EBITDA 0.19 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform.
Analysis Summary
Evogene Ltd. reported revenue of $3.9M in the most recent fiscal year, growing at a 5-year CAGR of 29.9%.
Trailing-twelve-month margins: gross margin -14.2%, operating margin -10.2%, net margin -7.0%.
At the current price of $0.50, EVGN has negative trailing earnings (P/E not meaningful) and an ROE of 7.66%. Market capitalisation stands at $4M.
Balance sheet quality for EVGN: current ratio of 4.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -1.98 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3.58 |
| vs Current Price | -822.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EVGN | Evogene Ltd. | $4M | 7.7% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | IL |
Profitability
| Return on Equity | 766.01% |
| Return on Invested Capital | -121.41% |
| Return on Assets | -68.20% |
| Gross Margin | -14.16% |
| Operating Margin | -1020.35% |
| Net Margin | -696.26% |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · GLTO
Explore sector: Healthcare · Biotechnology
More sections of EVGN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks